**Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins**

Alejandro López-Requena1,2,3, Oscar R. Burrone1 and Michela Cesco-Gaspere1 *

1 Molecular Immunology Group, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
2 Immunobiology Division, Center of Molecular Immunology, Havana, Cuba
3 Biotechnology Research Institute, Biotech Pharmaceutical Co, Ltd, Beijing, China

*Correspondence:
Michela Cesco-Gaspere, Molecular Immunology Group, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy.
e-mail: cesco.gaspere@gmail.com

Immunoglobulins (Ig) are glycoproteins formed by two identical heavy and two identical light polypeptide chains. The N-terminal ends of each pair of heavy-light chains consist of two variable (V) immunoglobulin (Ig) domains (VH and VH) that form a unique surface for antigen binding. V regions are generated during B cell ontogeny by the so-called V(D)J rearrangement of the germ-line Ig genes. This genetic rearrangement allows for the tremendous initial diversity of human Ig in naïve B cells, a critical feature of the immune system, which is further increased and reshaped by somatic hyper-mutation of V regions in antigen-stimulated mature B cells.

The association of the two V domains generates the idiotypic (Id), a distinctive structure and a unique collection of antigenic determinants called idiotypes. Idiotypes derive mainly from the CDR regions of the Ig V domains, frequently found to be of a conformational nature and derived from somatic mutations (Figure 1). Despite being self-proteins Ids can be immunogenic. For this reason Ids have been exploited as therapeutic immunogens in cancer treatment in two well-defined and clearly distinct contexts: (i) directly as a tumor-specific target on membrane Ig of the malignant B cell. Because of their clonotypic origin the Id expressed by malignant B cells represent true idiotypic antigens (Anderson et al., 1984). Therapeutic strategies that target the unique structure of the Id of each malignant clone constitute therefore a powerful tool for the treatment of B cell malignancies (Bendandi, et al., 1998; Sendtner and Dotto, 2009; Figure 2A). These strategies are essentially based on the generation of an anti-Id antibody and/or T cell-based immune response against antibody variable regions. Different strategies are currently used to strengthen Id immunogenicity, such as concomitant use of immune-stimulating molecules, design of Id-containing immunogenic recombinant proteins, specific targeting of relevant immune cells, and genetic immunization. This review focuses on the role of anti-Id vaccination in cancer management and on the current developments used to foster anti-idiotypic B and T cell responses.

Keywords: idiotypa, lymphoma, vaccines, cancer, idiotypic network

Idiotypic (Id)-based immunotherapy has been exploited as cancer treatment option. Conceived as therapy for malignancies bearing idiotypic antigens, it has been also extended to solid tumors because of the capacity of anti-idiotypic antibodies to mimic Id-unrelated antigens. In both these two settings, efforts are being made to overcome the poor immune responsiveness often experienced when using self immunoglobulins as immunogens. Despite bearing a unique gene combination, and thus particular epitopes, it is normally difficult to stimulate the immune response against antibody variable regions. Different strategies are currently used to strengthen Id immunogenicity, such as concomitant use of immune-stimulating molecules, design of Id-containing immunogenic recombinant proteins, specific targeting of relevant immune cells, and genetic immunization. This review focuses on the role of anti-Id vaccination in cancer management and on the current developments used to foster anti-idiotypic B and T cell responses.

**Figure 1**

Antigen mimicry is, however, a still not completely understood phenomenon. The concept is based on the idea that if both the antigen and the Id of the Ab2 bind to the antigen-combining site of Ab1 (paratope), then the paratope of the Ab2 would structurally resemble the antigen (Figure 2B). While in some examples structural homology between antigen and the Ab2 Id has been demonstrated to a certain extent (Pride et al., 1992; Chatterje et al., 1998; Spendlove et al., 2000; Chang et al., 2005), this is hardly the case when it comes to non-protein antigens (Talavera et al., 2009). Nevertheless, irrespective of the molecular basis of mimicry, the fact is that some Ab2 induce antibodies that bind to the antigen. The strategy of active immunotherapy with anti-idiotypic vaccines...
has been widely explored in cancer (Bhattacharya-Chatterjee et al., 2002; Lopez-Requena and Burrone, 2009).

Thus, an Ig Id can be conceived and used as an antigen to induce anti-Id responses in two different frameworks: (i) the Id itself as a target antigen on tumor cells, as in the case of B cell lymphomas (Figure 2A), and (ii) the Id as a mimic of a tumor antigen, with the anti-Id response ultimately intended to target the latter (Figures 2B,C). There is, however, an important distinction between the two cases. While the Id expressed on a tumor cell is a self-antigen, and therefore immunological tolerance is expected, this is not the case when it is used as a mimic of another antigen. In addition, Ab2 are frequently obtained in mice, for which the whole Ig is a foreign antigen for the patient. The response against the Id can thus be favored, and the constant region can act as a xenogeneic carrier. Nevertheless, in cases when the mouse antibody is not highly immunogenic immune-stimulating compounds are required to enhance the response (McCaffery et al., 1996).

Despite encouraging results at the preclinical level, Id-based immunotherapy has given disappointing outcomes in patients. Immunization with lymphoma Ids or anti-idiotypic antibodies mimicking tumor antigens has been demonstrated to be feasible and safe in clinical trials, despite proof of clinical efficacy is still awaited (de Cerio et al., 2007). Initial phase III clinical trials using Id vaccines in lymphoma patients did not meet their primary end points (Bendandi, 2009; Kannan and Nieda, 2009; Revnai and de Lavallade, 2011), highlighting the need for deeper research in both, the identification of predictors of the immune response in patients (Inoges et al., 2011a) and the design of clinical studies (Bendandi, 2009; Inoges et al., 2011b). Also, the improvement of vaccination strategies is an important issue under intense investigation (Bhattacharya-Chatterjee et al., 2002; Hollander, 2009; Revnai and de Lavallade, 2011). The last issue will be the focus of this review.

IMMUNE-STIMULATING CARRIERS AND ADJUVANTS

In 1975, Herman Eisen reported the first case of induction of active immunity to a tumoral Id in a murine plasmacytoma model (Eisen et al., 1975). Vaccination with the idiotypic protein, obtained and purified from plasma, was efficient to protect animals against subsequent tumor challenge. However, the possibility of establishing an anti-Id response in patients with Ig-secreting tumors was low, and attention turned to lymphomas where tumor cells display membrane bound Ig but secrete little. Pioneering studies in several murine lymphoma models demonstrated that the low immunogenicity of idiotypic protein can be efficiently overcome when Id was linked to a strong immunological carrier such as keyhole limpet hemocyanin (KLH). Using this approach, induction of high titers of anti-Id antibodies and protection against tumor challenge was demonstrated (Campbell et al., 1987, 1990; Kaminski et al., 1987; George et al., 1988), even in animals with established lymphoma (Campbell et al., 1988), suggesting that, although nominally self-antigens, idiotypic determinants can become immunogenic when administered in a context that allows overcoming T cell tolerance. The experience gained in murine studies led to the first clinical trials of patients with low-grade, follicular lymphoma, primarily those in first remission following chemotherapy (Kvsk et al., 1992). While this study reported the induction of an Id-specific humoral response, neither the activation of Id-specific T cells nor clinical efficacy were described. A phase II clinical study conducted by the National Cancer Institute first demonstrated clinical efficacy upon immunization with Id protein coupled to KLH and co-administered with granulocyte-monocyte colony stimulating factor (GM-CSF). The study described the clearance of residual tumor cells and long-term disease-free survival in follicular lymphoma patients in first complete remission after standard chemotherapy (Bendandi et al., 1999). The correlation between Id-specific immune response and in vivo control of minimal residual disease was also found in a similar study conducted in Europe (Barrion et al., 2002). More recently, clinical benefit associated to KLH-conjugated Id vaccines in lymphoma patients was reported in small phase II trials (Inoges et al., 2006; Redfern et al., 2006; Timmerman et al., 2009). However, clinical phase III studies aimed at obtaining regulatory approval for Id vaccines failed to reach their primary endpoints (Bendandi, 2009; Schuster et al., 2011a). Many factors have been taken into account as possible predictors of vaccination efficacy and induction of a clinically relevant immune response. In a recent double-blind multi-center controlled phase III trial in patients with follicular lymphoma, the outcome of vaccination with the patient-specific hybridoma-derived Id was dependent on the tumor Ig isotype, with IgM being significantly more effective than IgG (Schuster et al., 2011b). Despite the existence of Ids with an “intrinsic” ability to generate a syngenic immune response irrespective of the format (Lopez-Requena et al., 2007b), the IgM isotype has been associated with immunogenicity in contrast to the IgG (Reitan and Hennestad, 1995, 2001, 2002), which was shown in turn, to contain epitopes in the Fc region able to activate regulatory T cells (De Groot et al., 2008). With the aim of improving vaccine efficacy in patients, the possibility that Id-KLH cross-linking with glutaraldehyde may damage critical immunogenic epitopes, has prompted researchers to look for alternative reagents. Murine and patient-derived human Id-KLH vaccines generated using maleimide-based conjugation were found to be superior to glutaraldehyde conjugation to generate anti-Id immune responses (Kafi et al., 2009).
Conjugation to KLH has also been used in the context of antigen-mimicking anti-idiotypic vaccines. As examples, immunization of melanoma patients with the mouse anti-idiotypic antibody MK2-23, mimicking the high molecular weight-melanoma associated antigen (HMW-MAA), was significantly more efficient in inducing anti-anti-idiotypic antibodies when conjugated to KLH and administered in association to Bacillus Calmette-Guérin (BCG; Mittelman et al., 1995). Similarly, the murine anti-idiotypic antibody 3H1, which mimics a specific epitope of carcinoembryonic antigen (CEA), when conjugated to KLH and emulsified in Freund’s adjuvant was found to be able to induce effective anti-CEA immune responses in animals (Saha et al., 2006b). Finally, immunization with KLH-coupled R24, a mouse monoclonal antibody (mAb) specific for the disialoganglioside 3 (GD3), which is over-expressed on transformed melanocytes, induced an anti-idiotypic cascade leading to the identification of...
an anti-idiotype mAb able to mediate cytotoxicity on human melanoma cell lysis (Bazanski et al., 2011).

Apart from KLH, GM-CSF has been extensively tested in numerous protein immunization studies (Tao and Levy, 1993; Chen et al., 1994; Kwik et al., 1996), which altogether demonstrated the capacity of this cytokine to improve vaccine efficacy in terms of ability to induce Id-specific responses. The immunostimulatory properties of GM-CSF have been recently compared to other cytokines. In a colon carcinoma cell model, the vaccine was effective in inducing protective anti-tumor immunity (Saha et al., 2006a). Other studies demonstrated that these two last compounds are better immune adjuvants as, in contrast to GM-CSF, their administration induced efficient protection in a murine myeloma model upon vaccination with Id-KLH protein (Hong et al., 2012). Similarly, CpG co-administration significantly improved the cellular anti-CEA response in transgenic mice expressing human CEA and vaccinated with the CEA-mimicking murine 3H1 mAb (Ab2). In a CEA-transfected murine colon carcinoma cell model, the vaccine was effective in inducing protective anti-tumor immunity (Saha et al., 2006a). Other cytokines that have been used in animals, as Id-fusion proteins, include IL-2 (Chen et al., 1994; Wang et al., 2005) and IL-4 (Chen et al., 1994).

Alum, QS-21, and BCG are adjuvants that have been used in the clinics in anti-idiotype vaccine formulations with different antigen-mimicking murine Ab2 mAbs (Mittelman et al., 1995; Foon et al., 1999; Birebent et al., 2003; Giaccone et al., 2005; Grisdale et al., 2011; Soriano et al., 2011). An interesting case is the Id of 1E10 mAb, which mimics a tumor-associated type of ganglioside (Alfonso et al., 2002; Díaz et al., 2003; Hernandez et al., 2005) and, when administered in patients as an anti-idiotype vaccine (ractotumomab) in alum, induces a set of antibodies that bind the ganglioside but not the 1E10 Id (Alfonso et al., 2002; Díaz et al., 2003; Hernandez et al., 2008), and a ganglioside-specific cellular response (Guthmann et al., 2006).

IMMUNOGENIC RECOMBINANT PROTEINS

Compared to hybridoma technology, the molecular rescue of the tumoral Id from patient’s lymphoma cells is a less-time consuming alternative. Reverse transcription-polymerase chain reaction (RT-PCR) with family-based V gene primers allows identification and isolation of V\(_4\) and V\(_\gamma\) region sequences directly from biopsy materials. The tumor-associated idiotypic V\(_4\) and V\(_\gamma\) chains can then be cloned and assembled into different formats [single chain Fv (scFv), Fab, or full-length Ig] for expression in mammalian, bacterial, insect, or plant cells (Bird et al., 1988; Gurunathan et al., 1995). As example, recombinant human and murine Id in scFv format produced in plants, an appealing option that allows rapid production and recovery of the recombinant protein, were found to be highly immunogenic without the need of KLH cross-linking, both in presence and in absence of adjuvant (Mc Cormick et al., 2008). scFv molecules can be also fused to immune-stimulating molecules. A fusion protein consisting of 3W23 murine B cell lymphoma scFv and tetanus toxin fragment C (TFC), produced in E. coli as inclusion bodies or using a cell-free protein synthesis system, induced anti-Id antibodies and was as effective as murine anti-IgM-KLH Id protein in increasing survival after tumor challenge (Patel et al., 2011).

Up to now, the only recombinant fragment assayed in the clinics in B cell lymphoma patients is the tumor Fab-Id produced in E. coli (Berrinetti et al., 2006; Navarette et al., 2011). In the case of an antigen-mimicking Ab2, the Fab\(_\prime\) fragment from rat BR3E4 mAb, which mimics the colorectal carcinoma-associated epotope CO17-1A, was administered to patients coupled to KLH and showed to be more effective than the whole uncoupled IgG in inducing humoral and cellular responses (Birebent et al., 2001, 2003).

Chimeric antibodies have been assayed at the preclinical level to increase Id immunogenicity. The 1E10 mAb expressed as a chimeric mouse-human IgG1 and administered to mice in PBS alone, was immunogenic in syngeneic mice and the induced anti-idiotype antibody response was dominant over the anti-xenogeneic human constant region response (Lop eza-Requena et al., 2003). In contrast, chimeric antibodies containing the 38C13 murine B cell lymphoma Id required coupling to KLH for inducing an anti-Id antibody response. However, when fused to GM-CSF, IL-2, or IL-4, these recombinant molecules elicited anti-tumor immunity when administered without carrier or adjuvant (Tao and Levy, 1993; Chen et al., 1994). Similarly, a fusion protein consisting of the HMW-MAA-mimicking chimeric MK2-23 Ab2 mAb linked to IL-2 was effective in enhancing immunogenicity without the need of coupling to KLH (Wang et al., 2005). Recombinant molecules containing a single xenogeneic IgG domain have also been designed for Id immunization. A bivalent Id protein, obtained by fusing the BCL1 murine B cell lymphoma scFv to the CH3 domain from human IgG1 as dimerizing unit (Li et al., 1997), was effective in inducing anti-Id antibodies when administered either with or without adjuvant (Benvenuti and Burrone, 2001).

DNA VACCINES

Compared with Id protein vaccines, direct vaccination with DNA encoding the lymphoma Id is logistically easier to use and cheaper to manufacture. In principle, it can provide longer antigen expression to enable a sustained stimulation of both humoral and T cell-mediated immunity (Benvenuti and Burrone, 2002). As in the case of the Id protein, initial DNA vaccination studies in murine models showed that the tumor-derived V regions alone are poorly immunogenic, but the relatively easy manipulation of the antigen-encoding cassette has facilitated the testing of several different designs to augment immunogenicity. This has been achieved by genetically linking the Id sequence to a cytokine sequence such as GM-CSF (Syregalas et al., 1996) or to different CD4\(^+\) T cell epi-

Top 10 articles in Tumor Immunity

1. DNA vaccines for cancer treatment
2. Immunotherapy for solid tumors
3. Engineered T cells for cancer therapy
4. Tumor vaccines: past, present, and future
5. Personalized immunotherapy
6. Cancer vaccines in clinical trials
7. Immunomodulatory drugs in cancer therapy
8. Cancer vaccine design principles
9. Adjuvants and bystander effects in cancer vaccines
10. Challenges and opportunities in cancer vaccine development

López-Requena et al. Idiotypes as vaccines in cancer treatments

Frontiers in Oncology | Tumor Immunity
November 2012 | Volume 2 | Article 159 | 4

"fonc-02-00159" — 2012/11/7 — 21:44 — page 4 — #4
effects depended on the pentamerization of the fusion protein and its binding to the GM1 ganglioside (Chen et al., 2009). On the same line, in the 38C13 murine B cell lymphoma model, Suryngdias et al. (1996) showed that provision of a DNA construct encoding a constant region of human Ig linked to the Id gene was required for specific induction of anti-Id antibodies. Moreover, vaccination with an Id-GM-CSF fusion construct resulted in enhancement of both anti-Id antibody levels and tumor protection. The scFv-Id gene was also fused to a DNA encoding an immuno-enhancing peptide derived from IL-1β and demonstrated induction of tumor immunity that protected mice from tumor challenge (Hakim et al., 1996). An alternative fusion gene between a scFv and a protein derived from a plant virus was described as a further way to provide T cell epitopes and induce protective immunity in lymphoma and myeloma (Baveljeva et al., 2001).

Although scFv is a popular format for the design of recombinant Id-based vaccines (Xing et al., 1998), dimeric proteins are frequently constructed by fusing the scFvs with a dimerization unit (Benvenuti et al., 2000; Fredriksen et al., 2006). In fact, bivalency was reported to be important for efficient anti-Id antibody induction and T cell activation by a scFv-based vaccine (Fredriksen and Bogen, 2007). In the BCL1 model the fusion of the scFv to the xenogenic CH3 domain from human IgG1 was found to efficiently induce anti-Id antibodies and protection upon tumor challenge (Benvenuti et al., 2000). The minimal immunizing unit that has been assayed is the heavy chain CDR3 (H-CDR3). A vaccine based on Id H-CDR3 fused to tetanus toxin (Tet) was protective in the 38C13 murine B cell lymphoma model (Iurescia et al., 2010).

One particularity of DNA vaccination is that the immunizing molecule is per se immunostimulatory. The non-immunogenic 1E10 mAb Id, in the context of a fusion protein with CH3 domain from mouse IgG1 (i.e., with no xenogenic carrier), induced a clear anti-idiotypic response by gene gun DNA immunization. The adjuvant properties of bacterial DNA seemed to be responsible for this outcome, as when the same recombinant construct was administered through recombinant adeno-associated virus (rAAV) infection no response at all was detected (Lopez-Requena et al., 2007a). In a contrasting result, the xenogenic human IgG3 hinge/CH3 were required for good antibody responses and tumor protection in the murine MOPC315 myeloma and A20 B cell lymphoma models, with a DNA vaccine encoding the respective dimeric scFv-Id fused to the MIP-1α chemokine, administered by intramuscular injection followed by electroporation. When the syngeneic counterparts were used, the vaccine failed to elicit protective immunity (Fredriksen and Bogen, 2007).

**VIRAL VECTORS**

Administration of naked DNA has the disadvantage that a large amount of the immunogen is degraded before entering the cells (Dupuis et al., 2000). The use of virus-based vectors can partially circumvent this problem allowing the efficient penetration of cells while mimicking natural infection (Chen et al., 1996). Concerning the employment of viral vectors as vehicle to Id delivery in vivo, preclinical studies were performed in two murine B cell lymphoma models (38C13 and BCL1) to address the vaccine efficacy of Id-encoding adenoviruses (Timmerman et al., 2001). It was demonstrated in both models that a single injection of Id-adenovirus provided protection from subsequent tumor challenge, which was equivalent, or superior to that obtained by standard Id-KLH protein vaccine. However, this protection was dependent on the inclusion of xenogenic Ig constant region. The ability of recombinant adenovirus encoding a lymphoma Id gene to induce humoral and T cell-mediated anti-Id responses was evaluated also in the A20 murine B cell lymphoma model. A single vaccination with an adenoviral vector encoding a scFv derived from the lymphoma tumor Id coupled to the human IgG1 Fc (Ad.A20hFc) elicited a specific anti-Id antibody response and protection in challenged animals (Armstrong et al., 2002).

Among non-replicative viruses, adeno-associated viruses (AAV) have been extensively explored as transgene delivery vectors for their capacity to infect mainly non-dividing cells, such as muscle cells, and to induce a long-term expression of the transgene. The potentiality of these vectors for immunotherapeutical purposes has been intensely explored (Manning et al., 1997; Durin et al., 1998; Liu et al., 2000; Xin et al., 2002). Overall, these studies demonstrated the reliable capacity of recombinant AAV (rAAV) to induce specific immunity to foreign antigens upon intramuscular, subcutaneous, and oral administration. In this regard, we explored the possibility to induce anti-Id immune responses by means of rAAV-mediated vaccinations. We demonstrated that immunization with two recombinant vectors, encoding the BCL1 murine B cell lymphoma scFv (IdBCL1) fused to the human IgG1 CH3 domain (IdHCDR3/CH3), induced significant anti-Id antibody titers one month from rAAV injection (Cesco-Gaspere et al., 2008). However, while a single intra-muscular injection of rAAV-IdHCDR3/CH3 produced efficient tumor rejection in vivo, anti-Id antibody titers were significantly lower compared to previous standard immunizations consisting of repetitive administration of plasmid DNA by gene gun. Interestingly, when biolistic and rAAV immunization were combined in a prime-boost vaccination regimen the anti-Id immune response was further improved with a concordant increase in tumor protection. The mechanism that drives the efficacy of the prime-boost phenomenon is not clearly identified. In most cases, the huge amount of antigen supplied by the recombinant virus, in this case rAAV, seems to guarantee a more robust expansion of the antigen-specific immune response primed by the initial vaccination with naked DNA.

**TARGETING OF ANTIGEN-PRESENTING IMMUNE CELLS**

Alternative ways to enhance immunogenicity of lds have been investigated to overcome the need of chemical cross-linking and adjuvants that may have deleterious side effects. Among them, immunization with autologous dendritic cells (DCs) pulsed with the Id protein or in vivo targeting of antigen-presenting cells (APCs) were tested. The first approach produced encouraging results in different clinical trials (Hsu et al., 1996; Timmerman et al., 2002). A combination of sequential administration of pulsed DCs and of Id-KHIL protein, was also found to be efficient in inducing both humoral and cellular anti-lymphoma Id immunity (Hsu et al., 2001). A more recent study reported the induction of protective immunity in two lines of transgenic mice by pulsing DCs with an anti-idiotypic antibody (6D12) mimicking Her-2/neu antigen (Saha and Chatterjee, 2010).
In an alternative setting, Id vaccines have been targeted to APCs by fusion with chemokines, CD40-ligand (CD40L) or antibodies specific for APC-restricted molecules. In a pioneering study, two chemokines, IFN-10 and MCP-3, were N-terminally fused to the Ids from two different lymphoma models in the scFv format, and delivered as plasmid DNA or purified proteins (Biragyn et al., 1999). The fusions elicited strong immune responses that protected from tumor challenge in both models and with both chemokines. The adjuvant effect was supposed to be due to targeting of the antigen to professional APCs where the receptor for chemokines is expressed. This view was suggested by the requirement of a physical link between the scFv-Id antigen and the functionally active chemokine. Using a similar vaccine design, the same group demonstrated that the chemokine fusion facilitates the presentation of the tumor Id by APC via the MHC class II pathway (Biragyn et al., 2004). Other chemokines have been exploited as targeting unit for APC priming, such as MIP-1α and RANTES. The presence of a xenogeneic dimerizing unit (human IgG3 CH3 domain) was found to be essential in inducing protective immune response in mice immunized with a vaccine consisting of a chemokine fused to the Id from a murine B cell lymphoma (Fredriksen and Bogen, 2007). A DNA vaccine consisting of the A20 murine B cell lymphoma Id in scFv format fused to the MCP-3 chemokine and administered in sites pretreated with cardiotoxin had a higher impact on overall survival of challenged mice than the scFv alone. The presence of the myotoxin, which recruited APCs by promoting sterile inflammation, was also advantageous for the efficacy of the vaccination (Qin et al., 2009).

Targeting of antigen to APCs can be achieved also by antibodies or scFv specific for APC-restricted molecules. A DNA immunogen encoding a bivalent tumor Id and an anti-MHC class II scFv antibody was able to induce in mice higher levels of anti-Id antibodies than in control animals that had received an unrelated targeting unit or in animals not expressing the specific class II allele. The immune response led to tumor protection in two murine models, the MOPC315 myeloma and the A20 B cell lymphoma (Fredriksen et al., 2006). It was demonstrated a superior priming capacity of APC derived from draining lymph nodes to activate antigen-specific T cells in vivo when animals were vaccinated with the MHC class II-specific plasmid. Concordantly, antigen-specific CD4+ T cells in lymph nodes were found to be more activated in these animals, consistent with a targeting effect due to enhanced uptake of protein by APC and presentation to CD4+ T cells. The same prototype construct, encoding a myeloma patient-derived Id, efficiently induced in mice specific anti-Id responses that were patient-specific and dependent on the targeting effect (Froyland et al., 2011).

CD40 has also been exploited as APC-targeting receptor. Fusion of a chimeric antibody containing the 38C13 murine B cell lymphoma Id to CD40L improved immunogenicity compared to administration of the antibody alone, to levels similar to those of an Id/GM-CSF fusion protein (Huang et al., 2004). In vivo targeting of CD40+ APCs with a vaccine consisting on the A20 murine B cell lymphoma Id and a CD40L antibody chemically conjugated to an anti-CD40 antibody induced more efficient tumor protection than a classic vaccination with Id-KLH plus GM-CSF. Monophosphoryl lipid A but not GM-CSF had a synergistic effect with the Id conjugated to the antibody (Carlring et al., 2012).

Recently, the 38C13 murine B cell lymphoma-derived scFv-Id was linked, in a diabody format, to a B cell targeting moiety constituted by an anti-CD19 scFv. The recombinant molecule was proven to bind to non-cognate B cells, which in turn stimulated Id-specific B cells. Animals vaccinated with this diabody developed potent Id-specific antibody and T cell responses comparable to
those induced by 38C13-KLH. Interestingly, such diabodies were produced in a cell-free protein expression system that allowed the preparation of proper amounts of vaccine in a few hours (Ng et al., 2012).

**ANTIBODIES VERSUS T CELL RESPONSES**

The evidences accumulated so far on tumor protection induced by anti-Id immunization do not allow to clearly define the main mechanism involved in the rejection of tumor cells. The understanding of this issue is of major relevance, since this may allow improving vaccine efficacy and prognosis of lymphoma patients.

In mouse models, protein-based vaccines were shown to work through an anti-Id antibody-dependent mechanism (Bacila et al., 1999; Timmerman and Levy, 2000) or through the induction of effector T cells (Biragyn et al., 1999). In human studies, clinically relevant immune responses induced by immunization with Id-protein or Id-pulsed DCs were dependent on the induction of Id-specific CD8+ T cells (Bendandi et al., 1999). Moreover, synthetic peptides derived from Id-gene framework region shared among lymphoma patients were able to induce cytotoxic responses (Trojan et al., 2000). These evidences indicated that malignant B cell can process and present class I-restricted peptides derived from Id-gene framework V regions. The study of Inoges et al. (2006) clearly reported the induction of a humoral and cytotoxic cellular immune response against Id in lymphoma patients immunized with KLH-coupled Id in association with GM-CSF.

Upon DNA immunization, the in vivo antigen synthesis and processing should favor the loading of antigenic peptides onto MHC class I molecules and the induction of cytotoxic T lymphocyte (CTL) responses only if the delivered DNA construct is expressed by APCs, which depends on the method of DNA delivery. However, by using a chimeric mouse/human IgG1 DNA vaccine delivered by intramuscular injection, it was shown that protection in the 38C13 murine B cell lymphoma model was not impaired by CD8+Id+ T cell depletion (Strynegasus and Levy, 1999).

Similarly, we demonstrated that anti-Id antibodies, were totally essential to confer tumor protection in the BCL1 murine B cell lymphoma model (Cesco-Gaspere et al., 2003), despite the fact that DNA was intradermally delivered by gene gun immunization, a method that allows expression of antigen also by dermal resident DCs (our unpublished observations). However, since we did not deplete any T cell subpopulation, a possible contribution of protective T cells in this model, in addition to antibodies, cannot be completely ruled out.

On the contrary, in the 38C13 as well as in the A20 murine B cell lymphoma models, protection was found to be dependent on CD4+ and CD8+ T cells, when animals were vaccinated with a DNA construct encoding the scFv-Id fused to two different chemokines (Biragyn et al., 1999). In addition, cytotoxic cell lines, with proliferative and cytotoxic activity against the A20 murine B cell lymphoma cell line, were efficiently generated from mice vaccinated with a scFv adenoviral vector (Armstrong et al., 2002). Interestingly, in some cases Id-specific CD4+ T cells have been found to be unique players in tumor rejection. In the murine A31 B cell lymphoma and ST33 myeloma models, protection induced by DNA vaccination with a scFv fused to potato X virus protein was clearly compromised upon in vivo depletion of CD4+ T cells (Saveljeva et al., 2001). Another study performed on this issue showed that tumor protection against B lymphoma cells was induced in absence of B cells, antibodies and CD8+ T cells in a T cell receptor (TCR)-transgenic mouse model specific for an MHC class II-restricted peptide of the α2 lg light chain derived from the MOPC215 plasmacytoma (Lundin et al., 2003).

Considering clinical trials, a positive correlation between anti-Id antibody response and overall survival was found in patients with follicular lymphoma receiving the Id-KLH plus GM-CSF vaccine. In contrast, the T cell response was not associated with clinical outcome, although this was attributed to the variability of the cellular assays (Az et al., 2009). In a trial with an Id vaccine in the Fab format, the cellular response correlated with higher progression-free survival in the group of patients receiving the vaccine as first line treatment, but not in those immunized after remission consolidation following chemotherapy (Navarette et al., 2011). Previous studies had indicated an association between T cell responses and clinical benefit (Bendandi et al., 1999; Inoges et al., 2006). In any case, the induction of Id-specific CTLs is almost always a desired feature. The use of GM-CSF in current clinical vaccine formulations is indeed directed to achieve this goal. Several evidences enrolled in clinical trials developed T cell responses against the immunizing Id (Mabouseth et al., 2011; Rezvani and de Lavallade, 2011). T cell specificities were mapped to peptides derived from the CDRs of V1 (Navarrete et al., 2011). Induction of V2-CDR3-specific CTLs was also achieved when immunizing mice with a plasmid encoding this peptide fused to tetanus toxin FeC (Bartz et al., 2010). In fact, DNA immunization is an excellent tool to induce cellular responses (Stevenson et al., 2011).

Another strategy to achieve cellular responses against the immunizing Id is vaccination with Id-pulsed DCs. In a small trial, autologous DCs incubated with the Id and KLH and re-administered to the patients activated T cells specific for the Id in half of them, although the relative contribution of Th1 and Th2 compartments in this response was not defined (Rollig et al., 2011). However, it has also been reported that immunization with DCs pulsed with conserved idiotopes shared by different Ids (i.e., peptides from J regions) can lead to activation of regulatory T cells and thus dampen the response against Id-specific idiotopes such as H-CDR3 peptides (Würnitz et al., 2011). In another approach, a shift toward Id-specific Th1 response was achieved in the A20 murine B cell lymphoma model using a complex mixture containing the Id DNA, MIP3-α chemokine, and a small interfering RNA to silence IL-10. This formulation induced CTL activation and protection after tumor challenge (Singh et al., 2011).

Furthermore, the anti-tumor effect of the MCP-3 chemokine-scFv DNA vaccine in combination with cardiolipin was dependent on the cellular response, as it was abrogated after T cell depletion, but independent of the humoral response, as protection was also achieved in B cell-deficient mice (Qin et al., 2009).

In the case of human antigen-mimicking Ab2 used in the clinics, the Id is neither foreign nor strictly self, but synergetic. It has been suggested that for T cell responses the presence of the human Fc could be advantageous (Durrant et al., 2001). The 105AD7 mAb, which mimics the complement regulatory protein CD55...
| Id-vaccine design | Target | Reference |
|-------------------|--------|----------|
| **Carrier and adjuvants** | | |
| Tumor Ig coupled to KLH + GM-CSF | Human lymphoma | Bendandi et al. (1999), Barrios et al. (2002), Inoges et al. (2006), Raffelt et al. (2008), Timmerman et al. (2009) |
| Tumor Ig coupled to KLH + CpG/OH-5TGM1 murine myeloma | Hong et al. (2012) |
| **Immunogenic recombinant proteins** | | |
| Tumor scFv fused to T37-FC | 38C13 murine B cell lymphoma | Patel et al. (2011) |
| Tumor scFv fused to human yL CH3 | BCL1 murine B cell lymphoma | Benvenuti and Burroni (2001) |
| Tumor Fab + GM-CSF | Human lymphoma | Bertinetti et al. (2006), Navarrete et al. (2011) |
| Chimeric tumor Ig fused to GM-CSF + IL-2, IL-4 | 38C13 murine B cell lymphoma | Tao and Levy (1993), Chae et al. (1994) |
| **DNA vaccines** | | |
| Tumor Ig H-CDR3 fused to T37-FC | 38C13 murine B cell lymphoma | Iurescia et al. (2010) |
| Tumor scFv fused to T37-FC | Murine A31 B cell lymphoma and 5T33 myeloma | King et al. (1998) |
| Tumor scFv fused to the coat protein of Potexvirus | Murine A31 B cell lymphoma and 5T33 myeloma | Seveleva et al. (2001) |
| Tumor scFv fused to human yL CH3 | BCL1 murine B cell lymphoma | Benvenuti et al. (2000) |
| Tumor scFv fused to B subunit of E. coli heat labile toxin | BCL1 murine B cell lymphoma | Chai et al. (2009) |
| Chimeric tumor Ig fused to GM-CSF | 38C13 murine B cell lymphoma | Synergalski et al. (1996) |
| **Viral vectors** | | |
| Tumor scFv fused to human yL CH3 in adenovirus vector | BCL1 murine B cell lymphoma | Cesco-Gaspere et al. (2008) |
| Chimeric tumor Ig in adeno-associated virus vector | Murine 38C13 and BCL1 B cell lymphomas | Timmerman et al. (2001) |
| **APC-loading/targeting** | | |
| Tumor scFv fused to CD19 or MIP-1α | 38C13 murine B cell lymphoma | Hakim et al. (1998) |
| Tumor scFv fused to MIP-1α or MCP-3 | Murine 38C13 and A20 B cell lymphomas | Bragun et al. (1999) |
| Tumor scFv fused to MIP-1α or RANTES | A20 murine B cell lymphoma | Qin et al. (2009) |
| Tumor scFv fused to human yL CH3/Hinge and to MIP-1α or RANTES | Murine A20 B cell lymphoma and MOPC315 myeloma | Fredriksen and Bogen (2007) |
| Tumor scFv fused to human yL CH3/Hinge and to an anti-MHC class II scFv | Murine A20 B cell lymphoma and MOPC315 myeloma | Fredriksen et al. (2006) |
| Tumor scFv fused to an anti-CD19 scFv (diabody) | 38C13 murine B cell lymphoma | Ng et al. (2012) |
| Chimeric tumor Ig fused to CD4OL | 38C13 murine B cell lymphoma | Huang et al. (2004) |
| Tumor Ig chemically conjugated to an anti-CD40 antibody | A20 murine B cell lymphoma | Carling et al. (2012) |
| Tumor Ig-loaded DCs | Human lymphoma | Hou et al. (1998), Timmerman et al. (2001) |

**Id, idiotypic; Ig, immunoglobulin; KLH, keyhole limpet hemocyanin; GM-CSF, granulocyte-macrophage-colony stimulating factor; CpG, oligodeoxynucleotides containing unmethylated CG dinucleotides; IFN-α, interferon alpha; scFv, single chain variable fragment; T37-FC, tetanus toxin fragment C; IL-2, interleukin 2; IL-4, interleukin 4; Fab, antigen binding fragment; IP-10, interferon inducible protein 10; MCP-3, monocyte chemotactic protein 3; MIP-1α, macrophage inflammatory protein 1 α; RANTES, regulated and normal T cell expressed and secreted; CD40L, CD40 ligand; DCs, dendritic cells; MHC, major histocompatibility complex.**
A pool of these Ab2, given in alum either unconjugated or conjugated to an adhesion molecule (Ep-CAM), were immortalized with Epstein–Barr virus to isolate anti-idiotypic antibodies (Steinitz et al., 1988). In one study, B lymphocytes from a patient with colorectal cancer treated with a mouse mAb, specific for the epithelial-cell adhesion molecule (Ep-CAM), were immortalized with Epstein–Barr virus to isolate anti-idiotypic antibodies (Steinitz et al., 1988). A pool of these Ab2, given in alum either unconjugated or conjugated to immunogenic peptides from the Bordetella pertussis toxin subunit S1, induced humoral and cellular responses against the antibodies and the Ep-CAM antigen (Fagerberg et al., 1995). In another study, immunization with the antigen or the Ab2 mAb with GM-CSF as adjuvant was compared. While both immunogens generated specific T cell responses, the Ab2 mAb did not induce anti-Ep-CAM antibodies (Mosolits et al., 2004b). The induction of antigen-specific T-cell responses was later confirmed in a trial where the recombinant antigen, the Ab2 mAb and a viral vector, or the direct recruitment of immune-related cells has allowed translating Id targeting by the immune system into therapeutic approaches for Ig-expressing tumors (Table 1). Treatment of several other malignancies can also involve Id-based vaccination, taking advantage of antigen mimicry by Ids. Solid evidences of clinical benefit are however still awaited, and more work is needed to unveil the mechanisms and factors that impact on the generation of therapeutic anti-Id immune responses.

**ACKNOWLEDGMENTS**

Michela Cesco-Gaspere was in part supported by Fondo Trieste to Molecular Immunology, IGBEB, Trieste, Italy. We apologize to authors whose work was not cited because constraints in manuscript length.

**REFERENCES**

Ai, W. Z., Tolvieron, R., Taal, R., Czernok, D., and Levy, R. (2005). Anti-idiotype antibody response after vaccination correlates with better overall survival in colorectal cancer patients treated with a mouse mAb, specific for the epithelial-cell adhesion molecule (Ep-CAM), were immortalized with Epstein–Barr virus to isolate anti-idiotypic antibodies (Steinitz et al., 1988). A pool of these Ab2, given in alum either unconjugated or conjugated to immunogenic peptides from the Bordetella pertussis toxin subunit S1, induced humoral and cellular responses against the antibodies and the Ep-CAM antigen (Fagerberg et al., 1995). In another study, immunization with the antigen or the Ab2 mAb with GM-CSF as adjuvant was compared. While both immunogens generated specific T cell responses, the Ab2 mAb did not induce anti-Ep-CAM antibodies (Mosolits et al., 2004b). The induction of antigen-specific T-cell responses was later confirmed in a trial where the recombinant antigen, the Ab2 mAb and a viral vector, or the direct recruitment of immune-related cells has allowed translating Id targeting by the immune system into therapeutic approaches for Ig-expressing tumors (Table 1). Treatment of several other malignancies can also involve Id-based vaccination, taking advantage of antigen mimicry by Ids. Solid evidences of clinical benefit are however still awaited, and more work is needed to unveil the mechanisms and factors that impact on the generation of therapeutic anti-Id immune responses.

**ACKNOWLEDGMENTS**

Michela Cesco-Gaspere was in part supported by Fondo Trieste to Molecular Immunology, IGBEB, Trieste, Italy. We apologize to authors whose work was not cited because constraints in manuscript length.

**REFERENCES**

Ai, W. Z., Tolvieron, R., Taal, R., Czernok, D., and Levy, R. (2005). Anti-idiotype antibody response after vaccination correlates with better overall survival in colorectal cancer patients treated with a mouse mAb, specific for the epithelial-cell adhesion molecule (Ep-CAM), were immortalized with Epstein–Barr virus to isolate anti-idiotypic antibodies (Steinitz et al., 1988). A pool of these Ab2, given in alum either unconjugated or conjugated to immunogenic peptides from the Bordetella pertussis toxin subunit S1, induced humoral and cellular responses against the antibodies and the Ep-CAM antigen (Fagerberg et al., 1995). In another study, immunization with the antigen or the Ab2 mAb with GM-CSF as adjuvant was compared. While both immunogens generated specific T cell responses, the Ab2 mAb did not induce anti-Ep-CAM antibodies (Mosolits et al., 2004b). The induction of antigen-specific T-cell responses was later confirmed in a trial where the recombinant antigen, the Ab2 mAb and a viral vector, or the direct recruitment of immune-related cells has allowed translating Id targeting by the immune system into therapeutic approaches for Ig-expressing tumors (Table 1). Treatment of several other malignancies can also involve Id-based vaccination, taking advantage of antigen mimicry by Ids. Solid evidences of clinical benefit are however still awaited, and more work is needed to unveil the mechanisms and factors that impact on the generation of therapeutic anti-Id immune responses.

**ACKNOWLEDGMENTS**

Michela Cesco-Gaspere was in part supported by Fondo Trieste to Molecular Immunology, IGBEB, Trieste, Italy. We apologize to authors whose work was not cited because constraints in manuscript length.

**REFERENCES**

Ai, W. Z., Tolvieron, R., Taal, R., Czernok, D., and Levy, R. (2005). Anti-idiotype antibody response after vaccination correlates with better overall survival in colorectal cancer patients treated with a mouse mAb, specific for the epithelial-cell adhesion molecule (Ep-CAM), were immortalized with Epstein–Barr virus to isolate anti-idiotypic antibodies (Steinitz et al., 1988). A pool of these Ab2, given in alum either unconjugated or conjugated to immunogenic peptides from the Bordetella pertussis toxin subunit S1, induced humoral and cellular responses against the antibodies and the Ep-CAM antigen (Fagerberg et al., 1995). In another study, immunization with the antigen or the Ab2 mAb with GM-CSF as adjuvant was compared. While both immunogens generated specific T cell responses, the Ab2 mAb did not induce anti-Ep-CAM antibodies (Mosolits et al., 2004b). The induction of antigen-specific T-cell responses was later confirmed in a trial where the recombinant antigen, the Ab2 mAb and a viral vector, or the direct recruitment of immune-related cells has allowed translating Id targeting by the immune system into therapeutic approaches for Ig-expressing tumors (Table 1). Treatment of several other malignancies can also involve Id-based vaccination, taking advantage of antigen mimicry by Ids. Solid evidences of clinical benefit are however still awaited, and more work is needed to unveil the mechanisms and factors that impact on the generation of therapeutic anti-Id immune responses.

**ACKNOWLEDGMENTS**

Michela Cesco-Gaspere was in part supported by Fondo Trieste to Molecular Immunology, IGBEB, Trieste, Italy. We apologize to authors whose work was not cited because constraints in manuscript length.
De Groot, A. S., Moise, L., McMurray, J. A., Vambery, E., Van, O. L., Moun-
gon, P., et al. (2008). Activation of natural regulatory T cells by IgF
detected peptide “Regoloids.” J. Immunol. 180, 5102–5111.
Daur, A., Albino, M., Akilom, R., Sauze, G., Toshi, M., Carda, M., et al. (2003). Immune responses in breast cancer patients immu-
nized with an anti-idiotype antibody targeting Nasea-containing gan-
gliosides. Clin. J. Immunol. 107, 80–89.
Drapak, M., Denti-Mini, M., Vito, C., Goldhberg, C., Selmi, J. M., Chen, M., et al. (2000). Distribution of DNA vaccines determines their immune-
gene after intramuscular injection in mice. J. Immunol. 165, 2883–2888.
Duan, L., Parson, J., Moss, R., Sopodiou, I., Carter, G., and Fait, F. (2000). Human anti-idiotype anti-
body clones can be good immunogens as they target FC receptors on antigen-
presenting cells allowing efficient stimulation of both helper and cyto-
\textit{cT} cells. J. Immunol. 92, 414–420.
Eisen, H. N., Takako, N., and Fall, S. (1973). Molecular immune to tumor-
specific antigens. Transplant. Prog. 7, 209–214.
Fagerberg, J., Stuutiz, M., Woggl, H., Askled, P., and Mejilid, P. (1995). Antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fon, K. W., Park, Y. H., and Levy, R. (1989). Amplification of DNA vaccines are potentiated by pro-
glued immunotherapy with an anti-
idiotype vaccine in high-risk and metastatic breast cancer patients. J. Immunother. 95, 213–223.
Fukumura, S., Linsky, M., and Levy, R. (1991a). Tumor antigen-presenting cells to antigen-presenting cells. 5, 660–667.
Fukumura, S., Linsky, M., and Levy, R. (1991b). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991c). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991d). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991e). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991f). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991g). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991h). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991i). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991j). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991k). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991l). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991m). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991n). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991o). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991p). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991q). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991r). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991s). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991t). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991u). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991v). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991w). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991x). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991y). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Fukumura, S., Linsky, M., and Levy, R. (1991z). Tumor antigen-presenting cells to antigen-presenting cells. 37, 6625–6631.
Idiotypes as vaccines in cancer treatments

J. L. López-Requena, A. Neamtu, O. R. Burrone, C. H. Ottensmeier

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 05 September 2012; accepted: 22 October 2012; published online: 09 November 2012

Citation: López-Requena A, Burrone OR, Ottensmeier C-H (2012) Idiotypes as immunogens: facing the challenge of reducing strong therapeutic immune responses against the variable region of immunoglobulins. Front. Oncol. 2:139. doi: 10.3389/fonc.2012.00139

This article was submitted to Frontiers in Tumor Immunity, a specialty of Frontiers in Oncology.

Copyright © 2012 López-Requena, Burrone and Cesco-Gaspere. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.